These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
131 related items for PubMed ID: 14687793
1. Serum enterolactone levels and the risk of breast cancer in women with palpable cysts. Boccardo F, Lunardi G, Guglielmini P, Parodi M, Murialdo R, Schettini G, Rubagotti A. Eur J Cancer; 2004 Jan; 40(1):84-9. PubMed ID: 14687793 [Abstract] [Full Text] [Related]
2. Enterolactone in breast cyst fluid: correlation with EGF and breast cancer risk. Boccardo F, Lunardi GL, Petti AR, Rubagotti A. Breast Cancer Res Treat; 2003 May; 79(1):17-23. PubMed ID: 12779078 [Abstract] [Full Text] [Related]
3. Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study. Guglielmini P, Rubagotti A, Boccardo F. Breast Cancer Res Treat; 2012 Apr; 132(2):661-8. PubMed ID: 22094938 [Abstract] [Full Text] [Related]
4. Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland. Pietinen P, Stumpf K, Männistö S, Kataja V, Uusitupa M, Adlercreutz H. Cancer Epidemiol Biomarkers Prev; 2001 Apr; 10(4):339-44. PubMed ID: 11319174 [Abstract] [Full Text] [Related]
5. Serum enterolactone concentration is not associated with breast cancer risk in a nested case-control study. Kilkkinen A, Virtamo J, Vartiainen E, Sankila R, Virtanen MJ, Adlercreutz H, Pietinen P. Int J Cancer; 2004 Jan 10; 108(2):277-80. PubMed ID: 14639615 [Abstract] [Full Text] [Related]
6. Circulating enterolactone and prostate cancer risk: a Nordic nested case-control study. Stattin P, Adlercreutz H, Tenkanen L, Jellum E, Lumme S, Hallmans G, Harvei S, Teppo L, Stumpf K, Luostarinen T, Lehtinen M, Dillner J, Hakama M. Int J Cancer; 2002 May 01; 99(1):124-9. PubMed ID: 11948503 [Abstract] [Full Text] [Related]
7. Plasma enterolactone and breast cancer risk in the Nurses' Health Study II. Xie J, Tworoger SS, Franke AA, Terry KL, Rice MS, Rosner BA, Willett WC, Hankinson SE, Eliassen AH. Breast Cancer Res Treat; 2013 Jun 01; 139(3):801-9. PubMed ID: 23760859 [Abstract] [Full Text] [Related]
8. Enterolactone concentrations and prognosis after postmenopausal breast cancer: assessment of effect modification and meta-analysis. Seibold P, Vrieling A, Johnson TS, Buck K, Behrens S, Kaaks R, Linseisen J, Obi N, Heinz J, Flesch-Janys D, Chang-Claude J. Int J Cancer; 2014 Aug 15; 135(4):923-33. PubMed ID: 24436155 [Abstract] [Full Text] [Related]
9. Plasma enterolactone and breast cancer incidence by estrogen receptor status. Olsen A, Knudsen KE, Thomsen BL, Loft S, Stripp C, Overvad K, Møller S, Tjønneland A. Cancer Epidemiol Biomarkers Prev; 2004 Dec 15; 13(12):2084-9. PubMed ID: 15598765 [Abstract] [Full Text] [Related]
10. Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and herceptin 2 receptor status. Zaineddin AK, Vrieling A, Buck K, Becker S, Linseisen J, Flesch-Janys D, Kaaks R, Chang-Claude J. Int J Cancer; 2012 Mar 15; 130(6):1401-10. PubMed ID: 21544804 [Abstract] [Full Text] [Related]
11. Serum enterolactone and prognosis of postmenopausal breast cancer. Buck K, Vrieling A, Zaineddin AK, Becker S, Hüsing A, Kaaks R, Linseisen J, Flesch-Janys D, Chang-Claude J. J Clin Oncol; 2011 Oct 01; 29(28):3730-8. PubMed ID: 21900115 [Abstract] [Full Text] [Related]
13. Plasma enterolactone and genistein and the risk of premenopausal breast cancer. Piller R, Chang-Claude J, Linseisen J. Eur J Cancer Prev; 2006 Jun 01; 15(3):225-32. PubMed ID: 16679865 [Abstract] [Full Text] [Related]
14. Prediagnostic plasma enterolactone levels and mortality among women with breast cancer. Olsen A, Christensen J, Knudsen KE, Johnsen NF, Overvad K, Tjønneland A. Breast Cancer Res Treat; 2011 Aug 01; 128(3):883-9. PubMed ID: 21340481 [Abstract] [Full Text] [Related]
15. Serum enterolactone concentration is not associated with prostate cancer risk in a nested case-control study. Kilkkinen A, Virtamo J, Virtanen MJ, Adlercreutz H, Albanes D, Pietinen P. Cancer Epidemiol Biomarkers Prev; 2003 Nov 01; 12(11 Pt 1):1209-12. PubMed ID: 14652283 [Abstract] [Full Text] [Related]
16. An incident case-referent study on plasma enterolactone and breast cancer risk. Hultén K, Winkvist A, Lenner P, Johansson R, Adlercreutz H, Hallmans G. Eur J Nutr; 2002 Aug 01; 41(4):168-76. PubMed ID: 12242585 [Abstract] [Full Text] [Related]
17. Circulating enterolactone and risk of breast cancer: a prospective study in New York. Zeleniuch-Jacquotte A, Adlercreutz H, Shore RE, Koenig KL, Kato I, Arslan AA, Toniolo P. Br J Cancer; 2004 Jul 05; 91(1):99-105. PubMed ID: 15226762 [Abstract] [Full Text] [Related]
18. Pre-diagnostic plasma enterolactone concentrations and breast cancer prognosis among postmenopausal women - The Danish Diet, Cancer and Health cohort. Kyrø C, Hansen L, Frederiksen K, Nørskov NP, Bach Knudsen KE, Eriksen AK, Holm M, Tjønneland A, Olsen A. Clin Nutr; 2018 Dec 05; 37(6 Pt A):2217-2225. PubMed ID: 29154112 [Abstract] [Full Text] [Related]
19. Risk of acute coronary events according to serum concentrations of enterolactone: a prospective population-based case-control study. Vanharanta M, Voutilainen S, Lakka TA, van der Lee M, Adlercreutz H, Salonen JT. Lancet; 2018 Dec 05; 354(9196):2112-5. PubMed ID: 10609816 [Abstract] [Full Text] [Related]
20. Serum enterolactone concentrations are low in colon but not in rectal cancer patients. Tuomisto A, Nørskov NP, Sirniö P, Väyrynen JP, Mutt SJ, Klintrup K, Mäkelä J, Bach Knudsen KE, Mäkinen MJ, Herzig KH. Sci Rep; 2019 Aug 01; 9(1):11209. PubMed ID: 31371751 [Abstract] [Full Text] [Related] Page: [Next] [New Search]